Pruritus In Rare Cholestatic Conditions
MIRMMirum PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for LIVMARLI/Maralixibat (IBAT Inhibitor) in Pruritus In Rare Cholestatic Conditions. The expected timing is based on the latest available company guidance and may change.
11/04/25:- EXPAND Ph3 rare cholestatic pruritus enrollment completes 2026; topline data expected H1 2027. 01/12/26:- EXPAND Phase 3 enrollment now expected in H1 2026; topline data timing accelerated to Q4 2026. 02/25/26:- EXPAND Phase 3 enrollment and Q4 2026 topline timing both reaffirmed for additional cholestatic pruritus settings. 03/16/26:- EXPAND Ph3 enrollment completed; topline data expected Q4 2026. 05/06/26:- EXPAND Ph3 LIVMARLI enrollment completion and Q4 2026 topline expectations reiterated for rare cholestatic pruritus settings. 08/05/26:- EXPAND Ph3 topline results reiterated for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.